186 related articles for article (PubMed ID: 32529651)
1. Prostate-specific membrane antigen expression in melanoma metastases.
Snow H; Hazell S; Francis N; Mohammed K; O'Neill S; Davies E; Mansfield D; Messiou C; Hujairi N; Nicol D; Harrington K; Smith M
J Cutan Pathol; 2020 Dec; 47(12):1115-1122. PubMed ID: 32529651
[TBL] [Abstract][Full Text] [Related]
2.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
9. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop.
Gupta M; Choudhury PS; Rawal S; Goel HC; Singh A; Talwar V; Sahoo SK
Hell J Nucl Med; 2017; 20 Suppl():156. PubMed ID: 29324926
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
13. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
14. Correlations of the
Karyagar SS; Karyagar S; Guven O
Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
[TBL] [Abstract][Full Text] [Related]
16. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
17. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Validation of PSMA Expression Measured by
Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
[No Abstract] [Full Text] [Related]
19. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]